Laparoscopic Adjustable Gastric Banding as a Treatment for Morbid Obesity in Adolescents


The purpose of this study is to determine whether the LAP-BAND system is safe and effective in morbidly obese adolescents.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: February 2013

Detailed Description

The aim of this research is to evaluate the safety and efficacy of the use of the Lap-Band system in the morbidly obese adolescent population in the United States. We also propose to take advantage of the opportunity for liver biopsy and the data collected for the FDA study in adolescents to answer several questions: 1) what is the true incidence of non-alcoholic fatty liver disease (NAFLD) and its variants in morbidly obese adolescents; 2) what is the course of the NAFLD disease in adolescents who have undergone weight loss, including the progression from steatosis to NASH/ fibrosis or the progression of NASH to cirrhosis? 3) What are the factors implicated in this progression and 4) Is there a link between the excess visceral fat, MS and NAFLD as assessed by parallel changes in metabolic syndrome (MS) and NAFLD following weight loss intervention. The LAPBAND may provide obese adolescents with a significantly less morbid and reversible surgical option for weight loss.


  • Device: Placement of an adjustable gastric band
    • Laparoscopic placement of an adjustable gastric band around the upper portion of the stomach and subsequent adjustments of the band via a subcutaneous port as needed to maintain appropriate restriction.

Arms, Groups and Cohorts

  • Experimental: 1
    • Adolescents between the ages 14 through 17 with a BMI of 40 or more or with a BMI of 35 or more and with an obesity related comorbidity will undergo placement of an adjustable gastric band

Clinical Trial Outcome Measures

Primary Measures

  • Weight loss
    • Time Frame: Every six months

Secondary Measures

  • Resolution of comorbidities
    • Time Frame: every six months
  • Assess the status of comorbidities and changes in quality of life scores from baseline.
    • Time Frame: every six months

Participating in This Clinical Trial

Inclusion Criteria

  • Ages 14 through 17 – BMI greater than 40 – BMI 35 to 40 and also having an obesity related comorbidity – Have a history of working in a multidisciplinary weight loss program utilizing nutritional training, behavior modification, and activity training Exclusion Criteria:

  • Subject history of congenital or acquired anomalies fo the gastrointestinal tract – Severe cardiopulmonary or other serious organic disease – Severe coagulopathy – Hepatic insufficiency or cirrhosis – History of bariatric gastric or esophageal surgery – History of intestinal obstruction or adhesive peritonitis – History of esophageal motility disorders – Type I diabetes

Gender Eligibility: All

Minimum Age: 14 Years

Maximum Age: 17 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University of Illinois at Chicago
  • Provider of Information About this Clinical Study
    • Principal Investigator: Bob Kanard, Visiting Assistant Professor/MD – University of Illinois at Chicago
  • Overall Official(s)
    • Robert Kanard, M.D., Principal Investigator, Division of Pediatric Surgery, UIC

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.